Company to host Clinical Update meeting and webcast on Monday, December 9 at 12:00 PM ET BOSTON , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor
BOSTON , Oct. 07, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced the closing of its initial public offering of
BOSTON , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. , a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced the pricing of its initial public offering of 5,666,667 shares
August 5, 2019 —BOSTON, MA. and STOCKHOLM, SWEDEN, August 5, 2019 – Aprea Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Scott Coiante as
April 16, 2019 —BOSTON, MA. and STOCKHOLM, SWEDEN, April 16, 2019 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that the U.S.
April 3, 2019 —Studies support synergistic role of p53 stabilization by APR-246 in combination with immuno-oncology agents BOSTON, MA. and STOCKHOLM, SWEDEN, April 3, 2019 – Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade
March 25, 2019 —BOSTON, MA. and STOCKHOLM, SWEDEN, March 25, 2019 – Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced the appointment of Dr. Eyal C.
February 27, 2019 —Janus Henderson Investors joins Investor Group BOSTON, MA. and STOCKHOLM, SWEDEN, February 27, 2019 – Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced that funds managed
January 7, 2019 —BOSTON, MA., and STOCKHOLM, SWEDEN, January 7, 2019 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that Christian S.
December 2, 2018 — 95% ORR (by IWG) in 20 evaluable patients 70% complete remission (CR) rate in 20 evaluable patients No dose-limiting toxicities to date BOSTON, MA. and STOCKHOLM, SWEDEN, December 2, 2018 – Aprea Therapeutics presented results at the 2018 ASH Annual Meeting from its Phase
